Table 2.

Novel non-JAK2 inhibitors in clinical trials for patients with myelofibrosis

Novel non-JAK2 inhibitors in clinical trials for patients with myelofibrosis

HDAC indicates histone deacetylase; DNMT, DNA methyltransferase; HSP90, heat shock protein 90; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositide 3-kinase; PTX-2, pentraxin-2; IMiD, immunomodulatory; TGF-β, transforming growth factor beta; PD-1, programmed cell death-1; Epha3, ephrin type-A receptor 3; and IAP, inhibitor of apoptosis protein.

Close Modal

or Create an Account

Close Modal
Close Modal